Search Results

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform. first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

at the GPCR-Targeted Drug Discovery Summit 2026 The meeting brings together 80+ senior leaders from biotech Sessions from InterAx Biotech, Northeastern University, and Function Therapeutics dig into this — moving Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies

and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr. They wrapped up the conversation by discussing job opportunities at Interax Biotech and their anticipation Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery The discussion concluded with a brief overview of job opportunities at Interax Biotech, with Aurelien

GPCR — Scaling Biotech Beyond the Bench Turning scientific excellence into scalable organizations. Leadership 👉 Ambition is the default setting of biotech. This is the hidden cost of ambition in biotech leadership. Not failure. Not poo Attila Foris Mar 2 The Real Cost of Strategic Overload in Biotech 👉 In early-stage biotech, At the same time, the team is preparing for biotech fundraising.